T2 Biosystems to Host Conference Call to Discuss Awarding of Multi-Million Dollar BARDA Contract
September 10 2019 - 4:21PM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development
of innovative diagnostic products for critical unmet needs in
healthcare, announced today it will host a conference call and
webcast to discuss the up to $69 million milestone-based contract
it was awarded from the Biomedical Advanced Research and
Development Authority (BARDA), which will enable a significant
expansion of the Company’s current portfolio of diagnostics for
sepsis-causing pathogens and antibiotic-resistance genes.
Information related to the BARDA contract is available in an 8-K
filed with Securities and Exchange Commission today (available
here). The conference call with also cover the restructuring of the
Company’s term loan agreement with CRG Servicing LLC and its
Breakthrough Technology contract with Premier Inc.
Conference Call Management will host a
conference call with the investment community on Wednesday,
September 11, 2019 at 8:30 a.m. Eastern Time. Interested
parties may access the live call via telephone by dialing
1-877-407-9208 (U.S.) or 1-201-493-6784 (International) using
conference ID 13694458. To listen to the live call via T2
Biosystems' website, go
to www.t2biosystems.com, in the
Investors/Events & Presentations section. A webcast replay of
the call will be available following the conclusion of the call,
also in the Investors/Events & Presentations section of the
website.
About T2 Biosystems T2 Biosystems, a
leader in the development and commercialization of innovative
medical diagnostic products for critical unmet needs in healthcare,
is dedicated to improving patient care and reducing the cost of
care by helping clinicians effectively treat patients faster than
ever before. T2 Biosystems’ products include the T2Dx® Instrument,
T2Candida® Panel, and T2Bacteria® Panel, which was recently
announced as the first and only in-vitro diagnostic test to receive
approval for a New Technology Add-on Payment by the United States
Centers for Medicare & Medicaid Services, are powered by the
proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems
has an active pipeline of future products, including products for
the detection of additional species and antibiotic resistance
markers of sepsis pathogens, and tests for Lyme disease.
Media Contact: Gina Kent, Vault
Communications gkent@vaultcommunications.com
610-455-2763
Investor Contact: Zack Kubow, W2O Group
zkubow@w2ogroup.com 415-658-6436
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024